mRNA research and treatments

[Lilymoon]

New AI tool accelerates mRNA-based treatments for viruses, cancers, genetic disorders

A new artificial intelligence model can improve the process of drug and vaccine discovery by predicting how efficiently specific mRNA sequences will produce proteins, both generally and in various cell types.

The new advance, developed through an academic-industrial partnership between The University of Texas at Austin and Sanofi, helps predict how much protein cells will produce, which can minimize the need for trial-and-error experimentation, accelerating the next generation of mRNA therapeutics.

Messenger RNA (mRNA) contains instructions for which proteins to make and how to make them, enabling our bodies to grow and carry out the day-to-day processes of life. Among the most promising areas of health and medicine, the ability to develop new mRNA vaccines and drugs—able to fight viruses, cancers and genetic disorders—involves the frequently challenging process of coaxing cells in a patient's body to produce enough protein from therapeutic mRNA to effectively combat disease.


https://www.msn.com/en-us/health/other/ ... r-AA1Ji866


There no date on when this article was published.

[Lilymoon]

New mRNA Vaccine Shows Promise in Boosting Cancer Immunity



A new experimental mRNA vaccine could boost the immune system’s ability to fight cancer and improve the effectiveness of existing treatments, according to an animal study published July 18 in Nature Biomedical Engineering.

The vaccine utilizes messenger RNA (mRNA), the same technology that powers the first COVID-19 vaccines. Instead of targeting viruses, this approach activates the body’s innate immune system — its first line of defense — to recognize and attack cancer cells.

Researchers say this broad immune activation could help treat existing tumors and reduce the risk of recurrence.

https://greekreporter.com/2025/07/31/mr ... r-vaccine/

This one is fairly new July 31, 2025.

[firestar464]

why are you posting old news?

[Lilymoon]

I don’t see any news date on when article was posted?

[Lilymoon]

Scientists are testing mRNA vaccines to protect cows and people against bird flu

The bird flu outbreak in U.S. dairy cows is prompting development of new, next-generation mRNA vaccines — akin to COVID-19 shots — that are being tested in both animals and people.

Next month, the U.S. Agriculture Department is to begin testing a vaccine developed by University of Pennsylvania researchers by giving it to calves. The idea: If vaccinating cows protects dairy workers, that could mean fewer chances for the virus to jump into people and mutate in ways that could spur human-to-human spread.

Meanwhile. the U.S. Department of Health and Human Services has been talking to manufacturers about possible mRNA flu vaccines for people that, if needed, could supplement millions of bird flu vaccine doses already in government hands.

“If there’s a pandemic, there’s going to be a huge demand for vaccine,” said Richard Webby, a flu researcher at St. Jude Children’s Research Hospital in Memphis. “The more different (vaccine manufacturing) platforms that can respond to that, the better.”

The bird flu virus has been spreading among more animal species in scores of countries since 2020. It was detected in U.S. dairy herds in March, although investigators think it may have been in cows since December. This week, the USDA announced it had been found in alpacas for the first time.

https://apnews.com/article/bird-flu-mrn ... 9205a97ff7

[wjfox]

Thank goodness RFK Jr is taking care of that mRNA problem, by cutting $500 million in research funding.

We wouldn't want people getting cured of cancer now, would we?

[wjfox]

[weatheriscool]

[weatheriscool]

New nanoparticle mRNA vaccine may be cheaper and 100 times more powerful
By Malcolm Azania
November 14, 2025

Researchers at MIT have just developed a new lipid nanoparticle that super-enhances the effectiveness of the mRNA vaccine in mice to a hundred times its stand-alone effectiveness, thus offering massive savings by reducing required dosages while also reducing toxicity in the liver.

In their Nature Nanotechnology paper “Degradable cyclic amino alcohol ionizable lipids as vectors for potent influenza mRNA vaccines,” lead authors Arnab Rudra and Akash Gupta from the Koch Institute, MIT graduate student Kaelan Reed and colleagues explain that their nanoparticle-enhanced mRNA vaccine “significantly enhance[s] the potency of mRNA vaccines, and our structural insights may guide the development of next-generation vaccine delivery systems.”

In a press release, Gupta enthuses that his team’s new method works “much better than anything that has been reported so far. That’s why, for any intramuscular vaccines, we think that our [liquid nanoparticle] platforms could be used to develop vaccines for a number of diseases,” including COVID-19 and influenza.

https://newatlas.com/medical-tech/nanop ... -powerful/

[firestar464]

[weatheriscool]

[weatheriscool]

Hybrid polymer nanocarriers improve pulmonary mRNA vaccine delivery
https://phys.org/news/2026-01-hybrid-po ... -mrna.html

An LMU research team led by Professor Olivia M. Merkel, Chair of Drug Delivery at LMU, has developed a new delivery system for inhalable mRNA vaccines. Published in the journal Cell Biomaterials, the study presents a novel combination of poly(lactic-co-glycolic acid) (PLGA) and poly(β-amino esters) (PBAEs) designed to overcome key biological barriers in the lungs.

"Effective mucosal vaccination via inhalation requires carrier systems that can penetrate airway mucus while protecting the fragile RNA molecules they carry," explains Merkel. Once the lung barrier is overcome, the nanocarriers have to escape from the tiny vesicles (endosomes) that are transporting them and efficiently introduce (transfect) the mRNA into immune cells, which then present the corresponding antigens on their surface.
Stable and efficient transport system

[wjfox]

Moderna is curbing investment in vaccine trials due to US backlash

by Gerry Smith
• 3d • 2 min read

Moderna Inc.’s chief executive officer said the company doesn’t plan to invest in new late-stage vaccine trials because of growing opposition to immunizations from US officials.

“You cannot make a return on investment if you don’t have access to the US market,” Stéphane Bancel said in an interview with Bloomberg TV from the World Economic Forum in Davos, Switzerland. Regulatory delays and lack of support from US health officials are making the potential market size “much smaller,” he said.

Bancel’s comments are some of his strongest yet about the difficulties that vaccine makers face in the Trump administration. He joins a chorus of other pharmaceutical executives who have started to vent their frustrations with the government’s assault on immunizations.

[...]

Under the leadership of Health Secretary Robert F. Kennedy Jr., a vaccine critic, US officials have narrowed the population of people who are eligible for Covid vaccines, created confusion over how to get them and raised questions over their safety. That’s made things even harder for Moderna, which was already struggling from a post-pandemic decline in its Covid business.

Moderna is trying to transition from a company largely focused on Covid shots to one that makes personalized cancer treatments. The company has said it’s seeking outside funding to run late-stage trials of its other vaccines that protect against viruses that can lay dormant and undetected in the body after an infection, like Epstein-Barr virus and herpes simplex virus.

https://www.msn.com/en-us/politics/gove ... ngNewsVerp

[weatheriscool]

[weatheriscool]

[weatheriscool]